This week saw the University of Oxford’s Old Road Campus play host to the Mighty Quiz and raffle, in support of Alzheimer’s Research UK. Quizzers from various groups and posts came together to battle it out for the title of Mightiest Quizzers, and to raise money for dementia research and awareness. Once teams had tackled the first task – choosing an award-winning name – they went head to head, answering general knowledge questions on a variety ...
External Link found on http://aruk-oddi.medsci.ox.ac.uk/latest-news
FORMA Therapeutics and the University of Oxford Announce Multi-Year Collaboration to Advance the Development of Deubiquitinating Enzyme (DUB) Inhibitors for the Treatment of Neurodegenerative Diseases
Oxford, U.K. and Watertown, Massachusetts, USA – May 9th, 2018 – FORMA Therapeutics and the University of Oxford announced today they have entered into a collaboration and license agreement to identify, validate and develop deubiquitinating enzyme (DUB) inhibitors for the treatment of neurodegenerative diseases..
Researchers in London have identified a promising approach for tackling the hallmark Alzheimer’s disease protein, tau. The findings of the research, which was funded by Alzheimer’s Research UK, are published today (Monday 7 May) in the scientific publication Acta Neuropathologica Communications.
The research team are now working with experts from the Alzheimer’s Research UK Oxford Drug Discovery Institute to further assess the potential of targeting TAOKs to treat diseases like Alzheimer’s, and to develop this work towards something that could help people with dementia.
Alzheimer’s Research UK Oxford Drug Discovery Institute has teamed up with the University of Manchester and the Phenomics Discovery Initiative to identify small molecule inhibitors of NLRP3 inflammasome.
Oxford Drug Discovery Institute Chemist Stephen Wren will be running the London Marathon April 2019, in support of Alzheimer’s Research UK! Please click the link above to support him.
BMC On Health: Simon Lovestone discusses the failures of animal models in Alzheimer's research, and how new work on induced pluripotent stem cells, published in Alzheimer's Research & Therapy, could point the way to solving these.
A review led by Professor Simon Lovestone, theme lead at the NIHR Oxford Health Biomedical Research Centre, has found the first unambiguous signs of Alzheimer’s disease in a wild animal.
“It is very rare to find signs of full-blown Alzheimer’s Disease in non-human brains,” said Professor Lovestone, who is a researcher within the Oxford University Department of Psychiatry and is the Informatics / Digital Health theme lead at the NIHR Oxford Health BRC. “This is the first time anyone has found such clear evidence of the protein plaques and tangles associated with Alzheimer’s Disease in the brain of a wild animal.”
On Friday 29 September hundreds of researchers took to Oxford’s streets, gardens, museums and libraries to take part in the Curiosity Carnival, an event which celebrated and debated the way that research affects all our lives. Part of European Researcher’s Night, it was one of hundreds of events taking place across Europe. John Davis, CSO of Alzheimer’s Research UK Oxford Drug Discovery Institute, went along to talk about our research.
Last week was Dementia Awareness week, and here at Alzheimer’s Research UK Oxford Drug Discovery Institute we collaborated with the Oxford Health NHS Trust to put together a stall for a local science fair, organised by Living Well Oxford.
Scientists and organisations came together to offer practical advice and information on ageing and dementia, as well as a chance to understand the science behind getting older. Researchers from the Oxford Drug Discovery Institute and Oxford Health NHS Trust discussed their research and spoke to people about dementia, all facilitated through hands-on activities.
Dr Francesca Nicholls works in Oxford University's Alzheimer's Research UK Drug Discovery Institute. She uses cellular models to test potential drugs to fight dementia. Filmed by Educational Media Services, University of Oxford, at the Alzheimer's Research UK Oxford Drug Discovery Institute.
Do you want to know more about dementia? This Dementia Awareness Day (25th March 2017), members of the Alzheimer’s Research UK Oxford Drug Discovery Institute will be speaking at a Public Open Day at the John Radcliffe Hospital. The event is aimed at any members of the public with an interest in Dementia. We will have talks on current Dementia research in the region, a Q&A session, information stands, and interactive exhibits where you can find out more about services and support available in the area. Come and meet the team and hear about our research!
A medicinal chemist from Aylesbury will be pulling on his running shoes to raise hundreds of pounds for Alzheimer’s Research UK. Dr Stephen Wren, 45, who is taking on the Surrey Half Marathon on March 12, started running when he turned 40 and has been doing marathons ever since. Stephen is a dementia researcher at the Alzheimer’s Research UK Oxford Drug Discovery Institute at the University of Oxford.
John Davis, CSO of Alzheimer’s Research UK Oxford Drug Discovery Institute discusses the importance of working on Alzheimer's Disease.
Today (11 October) is Ada Lovelace Day, an international celebration of the work and achievements of women in science, technology, engineering and maths. To celebrate and showcase the work of the amazing women in dementia research, we caught up with Elena Di Daniel who is Head of Biology at the Alzheimer’s Research UK Oxford Drug Discovery Institute (DDI). Elena received her PhD in Biology from University College London working on the mechanism of action of mood stabilizing drugs, and has accumulated over 15 years’ experience in the pharmaceutical industry...
Alzheimer’s disease is devastating both for those who suffer from it and for those who love them. It is also expensive. It’s estimated that the current worldwide cost of coping with Alzheimer’s is $818 billion. A cure for Alzheimer’s is not available and current treatments for the disease focus on mitigating symptoms rather than eliminating causes. Recent research has provided evidence that the memory loss associated with Alzheimer’s may be preventable and reversible. Now, new research published in the Proceedings of the National Academy of Sciences reports on a gene therapy treatment that stopped the development of Alzheimer’s disease dead in its tracks.